JP2022515721A - FAPαに特異的な二環式ペプチドリガンド - Google Patents

FAPαに特異的な二環式ペプチドリガンド Download PDF

Info

Publication number
JP2022515721A
JP2022515721A JP2021534207A JP2021534207A JP2022515721A JP 2022515721 A JP2022515721 A JP 2022515721A JP 2021534207 A JP2021534207 A JP 2021534207A JP 2021534207 A JP2021534207 A JP 2021534207A JP 2022515721 A JP2022515721 A JP 2022515721A
Authority
JP
Japan
Prior art keywords
peptide ligand
acid
peptide
fapα
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515721A5 (cg-RX-API-DMAC7.html
Inventor
シェン リューホン
ステイス キャサリン
ウォーカー エドワード
Original Assignee
バイスクルアールディー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイスクルアールディー・リミテッド filed Critical バイスクルアールディー・リミテッド
Publication of JP2022515721A publication Critical patent/JP2022515721A/ja
Publication of JP2022515721A5 publication Critical patent/JP2022515721A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021534207A 2018-12-13 2019-12-13 FAPαに特異的な二環式ペプチドリガンド Pending JP2022515721A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1820320.8A GB201820320D0 (en) 2018-12-13 2018-12-13 Bicyclic peptide ligands specific for FAPalpha
GB1820320.8 2018-12-13
PCT/GB2019/053535 WO2020120979A1 (en) 2018-12-13 2019-12-13 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPα

Publications (2)

Publication Number Publication Date
JP2022515721A true JP2022515721A (ja) 2022-02-22
JP2022515721A5 JP2022515721A5 (cg-RX-API-DMAC7.html) 2022-12-19

Family

ID=65147028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534207A Pending JP2022515721A (ja) 2018-12-13 2019-12-13 FAPαに特異的な二環式ペプチドリガンド

Country Status (6)

Country Link
US (1) US20220008545A1 (cg-RX-API-DMAC7.html)
EP (1) EP3894005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022515721A (cg-RX-API-DMAC7.html)
CN (1) CN113507961A (cg-RX-API-DMAC7.html)
GB (1) GB201820320D0 (cg-RX-API-DMAC7.html)
WO (1) WO2020120979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質(fap)標的イメージングおよび治療
CN111118063B (zh) * 2019-12-05 2023-04-18 吉林大学 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502825A (ja) * 2014-10-29 2018-02-01 バイサイクル・セラピューティクス・リミテッド Mt1−mmpに特異的な二環性ペプチドリガンド
JP2018515066A (ja) * 2015-03-17 2018-06-14 バイオンテック アーゲー がんの診断及び処置のための組成物及び方法
WO2018197893A1 (en) * 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176622A1 (en) * 2002-09-18 2005-08-11 Kerstin Kuhn-Wache Secondary binding site of dipeptidyl peptidase IV (DPIV)
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
ES2428869T3 (es) 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
EP4706663A3 (en) * 2011-08-30 2026-05-20 Trustees Of Tufts College FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502825A (ja) * 2014-10-29 2018-02-01 バイサイクル・セラピューティクス・リミテッド Mt1−mmpに特異的な二環性ペプチドリガンド
JP2018515066A (ja) * 2015-03-17 2018-06-14 バイオンテック アーゲー がんの診断及び処置のための組成物及び方法
WO2018197893A1 (en) * 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof

Also Published As

Publication number Publication date
EP3894005A1 (en) 2021-10-20
US20220008545A1 (en) 2022-01-13
GB201820320D0 (en) 2019-01-30
CN113507961A (zh) 2021-10-15
WO2020120979A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
JP2022514255A (ja) Psmaに特異的な二環式ペプチドリガンド
JP2022518695A (ja) Caixに特異的な二環式ペプチドリガンド
JP2022517442A (ja) Caixに特異的な二環式ペプチドリガンド
JP2022518210A (ja) インテグリンαvβ3に特異的な二環式ペプチドリガンド
JP2022514618A (ja) Pd-l1に特異的な二環式ペプチドリガンド
JP2022517698A (ja) インテグリンαvβ3に特異的な二環式ペプチドリガンド
JP2022514687A (ja) Pd-l1に特異的な二環式ペプチドリガンド
EP4053145B1 (en) Bicyclic peptide ligands specific for epha2
JP2022517040A (ja) Cd38に特異的な二環式ペプチドリガンド
JP7460523B2 (ja) EphA2に特異的な二環ペプチドリガンド
JP2022512478A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2022513223A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2022542291A (ja) EphA2に特異的な二環式ペプチドリガンド
JP2022517399A (ja) Cd38に特異的な二環式ペプチドリガンド
JP2022532134A (ja) Ox40に特異的な二環式ペプチドリガンド
JP2022513806A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2022515720A (ja) Il-17に特異的な二環式ペプチドリガンド
CN107148425A (zh) 对mt1‑mmp特异性的双环肽配体
CN113507961A (zh) FAPα特异性的双环肽配体
JP2023506083A (ja) Il-17に特異的な二環式ペプチドリガンド
HK40080423A (en) Bicyclic peptide ligands specific for epha2
HK40080423B (en) Bicyclic peptide ligands specific for epha2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702